Spread of the fascioliasis endemic area assessed by seasonal follow-up of rDNA ITS-2 sequenced lymnaeid populations in Cajamarca, Peru.

Fascioliasis is a worldwide emerging snail-borne zoonotic trematodiasis with a great spreading capacity linked to animal and human movements, climate change, and anthropogenic modifications of freshwater environments. South America is the continent with more human endemic areas caused by Fasciola hepatica, mainly in high altitude areas of Andean regions. The Peruvian Cajamarca area presents the highest human prevalences reported, only lower than those in the Bolivian Altiplano. Sequencing of the complete rDNA ITS-2 allowed for the specific and haplotype classification of lymnaeid snails collected in seasonal field surveys along a transect including 2007-3473 m altitudes. The species Galba truncatula (one haplotype preferentially in higher altitudes) and Pseudosuccinea columella (one haplotype in an isolated population), and the non-transmitting species Lymnaea schirazensis (two haplotypes mainly in lower altitudes) were found. Climatic seasonality proved to influence G. truncatula populations in temporarily dried habitats, whereas L. schirazensis appeared to be more climatologically independent due to its extreme amphibious ecology. Along the southeastern transect from Cajamarca city, G. truncatula and L. schirazensis shared the same site in 7 localities (46.7% of the water collections studied). The detection of G. truncatula in 11 new foci (73.3%), predominantly in northern localities closer to the city, demonstrate that the Cajamarca transmission risk area is markedly wider than previously considered. Lymnaea schirazensis progressively increases its presence when moving away from the city. Results highlight the usefulness of lymnaeid surveys to assess borders of the endemic area and inner distribution of transmission foci. Similar lymnaeid surveys are still in need to be performed in the wide northern and western zones of the Cajamarca city. The coexistence of more than one lymnaeid transmitting species, together with a morphologically indistinguishable non-transmitting species and livestock movements inside the area, conform a complex scenario which poses difficulties for the needed One Health control intervention.

Nutritional AMD treatment phase I (NAT-1): feasibility of oral DHA supplementation in age-related macular degeneration.

PURPOSE: To create a pilot study in order to evaluate the feasibility of a prospective case-control study of oral supplementation with fish oil (docosahexaenoic acid [DHA]; eicosapentaenoic acid [EPA]) in a population with age-related macular degeneration (AMD). METHODS: A homogeneous group of 38 patients with drusenoid pigment epithelial detachment in one eye (PED) without choroidal new vessels (CNV) was selected. A complete ophthalmologic examination, and a complete profile of fatty acids in serum (S) and in red blood cell membranes (RBCM), were recorded at day 0 and month 6. In group 1, 22 patients were orally supplemented with EPA (720 mg/day) and DHA (480 mg/day) during 6 months. In group 2, 16 patients were followed as controls. Nutritional recommendations on fish consumption were given to both groups. RESULTS: In group 1, after 6 months supplementation we observed a significant blood enrichment in EPA (EPA-S: 2.20 vs 0.79, p<0.0001 and EPA-RBCM: 2.24 vs 0.85, p<0.0001) and in DHA (DHA-S: 2.47 vs 1.56, p<0.0001 and DHA-RBCM: 6.47 vs 4.67, p<0.0001). No change was observed in group 2 despite nutritional recommendations. In this short followup, no evolution to CNV was noted in either of the two groups. Neither side effects nor dropouts were observed in either of the groups. DISCUSSION: This study supports the feasibility of a long-term double-masked prospective case-control study in an AMD population in order to evaluate a potential benefit from oral supplementation with DHA.

Cirrosis biliar primaria y glomerulonefritis a cambios mínimos / No disponible

No disponible

Long-term prognosis of hypertension in pregnancy.

OBJECTIVES: To assess the prevalence of subsequent hypertension in women with hypertensive pregnancies and evaluate it according to the subclassifications of hypertension in pregnancy. METHODS: A survey was carried out in 476 women with hypertensive pregnancies (cases) and 226 normotensive controls delivered between 1973 and 1991 in a tertiary-level teaching hospital. They were invited to participate by mail and 273 cases (57%) and 86 controls (38%) completed the analysis. Outcomes assessed were prevalences of hypertension, diabetes, and hypercholesterolemia, together with cardiovascular morbidity. RESULTS: Among responders, age and parity were similar in both groups although follow-up time was longer in controls. Subsequent hypertension was more frequent within cases. After excluding chronic and unclassifiable hypertension, the mean blood pressure was higher in all other forms of pregnancy hypertension (103 +/- 13 mm Hg versus 94 +/- 13 mm Hg, p < 0.001); long-term hypertension prevalence was 45% in cases and 14% in controls [odds ratio (OR) = 5.1; 95% confidence interval (95% CI) = 2.5-9.8; p < 0. 001]. There were no differences with respect to the prevalences of subsequent diabetes or hypercholesterolemia. Remote hypertension was more common following gestational hypertension (54%) than in preeclampsia (38%), eclampsia (14%), or normotensive cases (14%) (OR for gestational hypertension versus normotensives = 7.2; 95% CI = 3. 4-14.8, p < 0.001, and OR for preeclampsia versus normotensives = 3. 7; 95% CI = 1.7-7.9, p < 0.001). CONCLUSIONS: After an average of 13. 6 years since the index pregnancy, women with hypertensive pregnancies have an increased risk of subsequent hypertension. Gestational hypertension is the hypertensive disorder of pregnancy with the highest incidence of subsequent hypertension. Women with preeclampsia have a greater tendency to develop hypertension than women with normotensive pregnancies. By contrast, women with eclampsia do not.

Hipertensión arterial y menopausia reciente: estudio comparativo de dos fármacos hipotensores

Objetivo. Analizar durante doce semanas la eficacia antihipertensiva, tolerancia clínica y perfil metabólico del amlodipino y el carvedilol en mujeres hipertensas con menopausia de comienzo reciente. Diseño. Estudio prospectivo y aleatorio. Material y métodos. Cuarenta mujeres (edad media: 51,1 ñ 0,89 años; tiempo de menopausia: 1,6ñ0,53 años; meses desde el diagnóstico de la hipertensión arterial [HTA]: 20,70ñ9,31). Se excluye menopausia quirúrgica. Treinta y dos (80 por ciento) HTA grado I y 8 (20 por ciento) grado II de la Organización Mundial de la Salud (OMS). Previamente y durante dos semanas se suspendió el tratamiento previo: 16 (40 por ciento) no tratadas, 14 (35 por ciento) tratadas no controladas y 10 (25 por ciento) tenían intolerancia. Se establecieron dos grupos de tratamiento a los que las pacientes se asignaron de manera aleatoria: 20 pasaron a recibir 5 mg de amlodipino y las otras 25 mg de carvedilol, todas en dosis única por las mañanas. Al inicio y final del estudio se determinaron las cifras de presión arterial sistólica (PAS), presión arterial diastólica (PAD), frecuencia cardíaca, índice de masa corporal de Quetelet y analítica sanguínea: colesterol total y HDL, triglicéridos, glucosa, ácido úrico, creatinina, sodio y potasio. Consideramos que existía control de la presión arterial con cifras de PAS < 130 mmHg y de PAD < 85 mmHg. Se recogieron los efectos que cada paciente atribuía a la medicación del estudio. La significación estadística se estableció para una p < 0,05.Resultados. Se analizan los resultados de 37 pacientes; tres del grupo amlodipino se excluyeron por edemas en miembros inferiores. En ambos grupos se produjo un descenso (p < 0,001) de las cifras de PAS y de PAD, existiendo únicamente control de la PAD. La frecuencia cardíaca disminuyó (p < 0,01) en el grupo del carvedilol. No existieron diferencias significativas en el resto de los parámetros analizados. Efectos secundarios: 2 (10 por ciento) en el grupo del carvedilol y 5 (25 por ciento) en el de amlodipino. Conclusión. Ambos fármacos mostraron eficacia antihipertensiva y perfil metabólico neutro en el tratamiento de la HTA en la mujer postmenopáusica, con mejor tolerancia clínica del carvedilol (AU)

Major histocompatibility complex class I associations in iron overload: evidence for a new link between the HFE H63D mutation, HLA-A29, and non-classical forms of hemochromatosis.

The present study is an analysis of the frequencies of HFE mutations in patients with different forms of iron overload compared with the frequencies found in healthy subjects from the same region. The frequencies of HLA-A and -B antigens and HLA haplotypes were also analyzed in the same subjects. The study population included: 71 healthy individuals; 39 genetically and clinically well-characterized patients with genetic hemochromatosis (HH); and 25 patients with non-classical forms of iron overload (NCH), excluding secondary hemochromatosis. All subjects were HLA-typed and HFE-genotyped by the oligonucleotide ligation assay (OLA). The gene frequencies found for the C282Y and H63D mutations of HFE were respectively: 0.03 and 0.23 in healthy individuals, 0.86 and 0.04 in HH patients, and 0.08 and 0.48 in NCH patients. An expected significant association between HH and HLA-A3 was observed, which was found to be in linkage disequilibrium with the C282Y mutation. A new association was seen, however, between HLA-A29 and NCH, in linkage disequilibrium with the H63D mutation. Again as expected, the HLA-B antigen B7 was associated with HH in linkage disequilibrium with HLA-A3. In addition, the HLA-B antigen B44 was found to be associated with NCH but not in linkage disequilibrium with either A29 or the H63D mutation. In conclusion, a new association of the HFE H63D mutation with forms of hemochromatosis other than HH and a new association between the HLA phenotype A29 and the HFE H63D mutation were found in the same patients. These findings reinforce evidence for the involvement of the major histocompatibility class I in iron metabolism, supporting the notion of a physiological role for the immunological system in the regulation of iron load.

Herpes simplex virus encephalitis in a renal transplant patient: diagnosis by polymerase chain reaction detection of HSV DNA.

A case of herpes simplex virus (HSV) encephalitis with disseminated primary HSV infection in a renal transplant patient is described. The diagnosis of the disease was achieved by nested polymerase chain reaction (PCR)-DNA in cerebrospinal fluid (CSF). Other diagnostic measures (immunoglobulin [Ig] M and virological cultures both in blood and CSF) were negative. Blood IgG gave a false-positive signal. Although ganciclovir is not the drug of choice, its concomitant administration in our patient as a prophylactic measure against CMV infection may have decreased the usual severity normally expected in this kind of primary HSV infection. The subsequent increase in ganciclovir dose to full therapeutic range, which was implemented before the diagnosis was achieved, led to the disappearance of symptoms. The detection of PCR-DNA in CSF will probably become the diagnostic method of choice. One of its great advantages, in addition to its diagnostic reliability, is that it may obviate the performance of many cerebral biopsies.

Treatment of cyclosporin-induced gingival hyperplasia with azithromycin.

BACKGROUND: Gingival hyperplasia is a known complication of cyclosporin therapy. Although plaque control has been shown to be of benefit, gingival surgery is occasionally necessary. The aim of this study was to review the effect of a short-course therapy with azithromycin in renal transplant patients with cyclosporin-induced gingival hyperplasia. METHODS: Thirty-eight patients received 500 mg/day of azithromycin for 3 consecutive days. The degree of gingival hyperplasia was classified as: 0, no gingival overgrowth; 1, mild overgrowth; 2, moderate overgrowth, and 3, severe overgrowth. Gingival bleeding and evolution of gingival hyperplasia were determined at 0 (pretreatment), 7, 30, 90 and 180 days. Cyclosporin, serum creatinine and ALT levels were simultaneously determined on the same days. RESULTS: Seven patients were excluded, leaving a total of 31 included in the trial. Eleven had a score of 3, 17 a score of 2, and 3 a score of 1. The degree of gingival hyperplasia was unrelated to the dose and levels of cyclosporin. Gingival hyperplasia improved in all patients (P < 0.001, Friedman test). The degree of improvement was better when the degree of hyperplasia was lower. In 27 patients gingival hyperplasia remained absent 6 months later, 3 patients required a second course of treatment, and another required gingival surgery. Gingival bleeding, present in 28 patients when diagnosed, disappeared in all cases in 2.2 +/- 1.2 (1-7) days. No adverse effects were observed. Cyclosporin, serum creatinine, and ALT levels were not affected by treatment. CONCLUSIONS: Azithromycin improves cyclosporin-associated gingival hyperplasia, especially when administered early in the process.

[Lymphangioleiomyoma with retroperitoneal and thoracic involvement]. / Linfangioleiomioma con afectación retroperitoneal y torácica.

We report a new case of lymphangioleiomyoma in a 29 years old woman, with antecedents of recurrent spontaneous pneumothorax; she was diagnosed 2 years previously of retroperitoneal hemangiopericytoma, and she has admitted to the hospital because pneumothorax, chilotorax and honeycomb lung pattern, which induce to review the previous retroperitoneal biopsy and confirm to answer with lymphangioleiomyoma. The literature is reviewed.

Cytomegalovirus preemptive therapy with ganciclovir in renal transplant patients treated with OKT3.

In an attempt to decrease the prevalence and severity of cytomegalovirus (CMV) disease, preemptive therapy with ganciclovir was administered to all renal transplant patients treated with OKT3 between February 1993 and December 1994 (26 patients). The results were compared with those of a historical group treated with OKT3 but not with ganciclovir (29 patients). Both groups were similar in age, sex, number of previous transplants, number of rejections, serological status of donor and recipient and OKT3 dose. Ganciclovir was administered during the period of treatment with OKT3. Only 2 (7.7%) treated patients developed CMV disease versus 11 (37.9%) of the control group (p = 0.01). In the control group the intensity of the disease was severe in 7 (63.6%) cases, whereas in the treated patients it was always of slight intensity (p = 0.01). In conclusion, preemptive therapy with ganciclovir during treatment with OKT3 decreases the prevalence and severity of CMV disease.

Effect of di-n-propylacetate on the 'binding of GABA to synaptosome-enriched fraction of rat cerebral cortex.

The effect of di-n-propylacetate (DPA) on the 'binding' of gamma-aminobutyric acid (GABA) to a synaptosome-enriched fraction of rat cerebral cortex has been examined using differential centrifugation and double-isotope liquid scintillation spectrometry. DPA at 10(-4) M caused a slight decrease in GABA binding. This effect could explain in part the in vivo anticonvulsant and behavioral effects of this drug when administered to animals in high systemic doses.